Zogenix (ZGNX) Reports Positive Top-Line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Tweet Send to a Friend
Zogenix, Inc. (NASDAQ: ZGNX) today reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
